AC
BIOTU

Aristeia Capital’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Aristeia Capital’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,149,010
Closed -$11.5M – 650
2021
Q3 		$11.5M Hold
1,149,010
– – 0.21% 135
2021
Q2 		$11.6M Hold
1,149,010
– – 0.23% 135
2021
Q1 		$11.4M Buy
+1,149,010
New +$11.8M 0.22% 146

Other funds holding BIOTU

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 33.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Aristeia Capital's BIOTU Position: Q4 2021 in Review

Aristeia Capital sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2021, closing a stake of 1,149,010 shares — an estimated $11.5M sold.

Aristeia Capital first reported a position in BIOTU in Q1 2021 and held it in 3 quarters. The position peaked at $11.6M in Q2 2021. 15 funds tracked by Wall St. Rank hold BIOTU as of Q4 2021.

  • Aristeia Capital reported no remaining Biotech Acquisition Company Unit position as of Q4 2021 after selling out during the quarter.
  • Aristeia Capital sold 1,149,010 Biotech Acquisition Company Unit shares in Q4 2021, an estimated $11.5M.
  • Aristeia Capital first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 3 quarters.
  • Aristeia Capital's Biotech Acquisition Company Unit position peaked at $11.6M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2021.

Based on Aristeia Capital's 13F filing for Q4 2021, filed 14 Feb 2022.